1. Scrip
  2. >>Focus On Asia
  3. >>China

China’s Environmental Regs Put More Pressure On Pharma

 
• By Lauren Hilgers

As part of China’s five-year plan, environmental restrictions will increasingly get more attention, but punishments for lax companies will likely be tougher in urban areas where public awareness is greater.

SHANGHAI – At the end of 2011, China’s Ministry of Environmental Protection publicly ordered its local bureaus to issue harsh penalties in 12 pollution cases involving 15 pharmaceutical companies. The involvement of the national-level of the ministry is the latest in a string of pollution cases involving pharmaceutical companies – a sign, experts say, of the tightening enforcement of environmental regulations.

The pharmaceutical industry is one of the biggest contributors to China’s toxic chemical pollution. In a study released in 2009, the MEP estimated that, while the industry was responsible for 3% of China’s GDP, it also contributed 6% to the country’s overall emissions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

More from Focus On Asia